ImmuneSensor Therapeutics Email Format

Biotechnology ResearchTexas, United States2-10 Employees

ImmuneSensor Therapeutics develops medicines that modulate the cGAS-STING axis of the innate immune system to treat cancer and autoimmune diseases. It licenses technologies from the University of Texas Southwestern Medical Center, specifically from Dr. Zhijian Chen’s laboratory, whose work identified cGAS and cGAMP as triggers of STING-driven immune responses. Its lead program, IMSA101, aims to activate STING and is in clinical development for cancer therapy, while additional candidates include a cGAS inhibitor designed to dampen overactive autoimmunity. 

Based in Dallas, Texas, the company operates with a small team focused on research and development in biotechnology. In May 2024, ImmuneSensor appointed Thomas W. Dubensky, Jr., Ph.D., as president and chief executive officer and as a member of the board.

Sign up for free to view info

Company overview Employee directory